October is here and it's make it or break it for many small biotech companies. I am looking at AVNR, BIOD, and ALXA at the moment.
AVNR has good chance of approval while ALXA and BIOD are in doubts. Personally I think BIOD will be reject considering they ignore to correct the anomalies in their data.
Any of you guys into Biotechs?
AVNR has good chance of approval while ALXA and BIOD are in doubts. Personally I think BIOD will be reject considering they ignore to correct the anomalies in their data.
Any of you guys into Biotechs?
Comment